Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03549598 · ClinicalTrials.gov registry record · Phase 4
d68Ga-DOTATATE PET/CT Assessment of Cardiac Sarcoidosis
A Phase 4 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 4
- Development phase
- 15
- Enrollment target
NCT03549598: Completed Phase 4 study, sponsored by Mayo Clinic.
NCT03549598 is a Phase 4 study that has completed, run by Mayo Clinic. The registered enrollment target is 15 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03549598, a Phase 4 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 15 participants
- Enrollment target
Study Summary
The Researchers are trying to determine if 68Ga-DOTATATE PET/CT imaging will have a similar accuracy as 18FDG PET/CT in diagnosing cardiac sarcoidosis and if it will be able to do so without the need for complex patient dietary preparation that is required with 18FDG PET/CT.
Interventions
- DRUG 68Ga-DOTATATE PET/CT
- DRUG 18FDG PET/CT scan
- DRUG 13NH3 PET/CT scan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2018-07-20 |
| Est. Completion | 2019-10-02 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03549598
The ClinicalTrials.gov registry entry for NCT03549598 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which 68Ga-DOTATATE PET/CT is the first listed.
NCT03549598 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03549598 about?
NCT03549598 is a clinical study titled "d68Ga-DOTATATE PET/CT Assessment of Cardiac Sarcoidosis". The Researchers are trying to determine if 68Ga-DOTATATE PET/CT imaging will have a similar accuracy as 18FDG PET/CT in diagnosing cardiac sarcoidosis and if it will be able to do so without the need for complex patient dietary preparation that is required with 18FDG PET/CT.
What is the current status of trial NCT03549598?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 15 participants. The study started on 2018-07-20. Estimated completion is 2019-10-02.
What interventions are being tested in trial NCT03549598?
The interventions under investigation include: 68Ga-DOTATATE PET/CT (DRUG), 18FDG PET/CT scan (DRUG), 13NH3 PET/CT scan (DRUG).
Who is sponsoring clinical trial NCT03549598?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.